Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Prostate Cancer is Scopus-indexed (Q3, CiteScore 2.1), WoS ESCI, DOAJ. Published by John Wiley and Sons Ltd.
Checked against the index lists dated .
ISSN 2090-3111Verify ISSN ↗2090-312XVerify ISSN ↗
Publisher: John Wiley and Sons Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Urology | 73 / 123 | 41st | Q3 |
| Oncology | 293 / 428 | 31st | Q3 |
| Cancer Research | 191 / 233 | 18th | Q4 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2013–present (also 2011), best quartile Q3, CiteScore 2.1.
Prostate Cancer is Q3 in Urology (rank 73 of 123), Q3 in Oncology (rank 293 of 428) and Q4 in Cancer Research (rank 191 of 233), by CiteScore 2025.
Prostate Cancer is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.1, which places it in quartile Q3 at the 41st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.602, quartile Q2, with an H-index of 17.
The publisher lists an article processing charge of about US$1,000 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Prostate Cancer is published by John Wiley and Sons Ltd. Its print ISSN is 2090-3111 and its online ISSN is 2090-312X.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Prostate Cancer has an h-index of 38 and a 2-year mean of 1.15 citations per paper (OpenAlex). Its Scopus CiteScore is 2.1, quartile Q3. On 2-year citations it ranks #64 of 123 Scopus journals in Urology.
Prostate Cancer published 13 papers in 2025; its busiest recent year was 2018 with 37. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 52 research articles (2021–2026), authors are most often from United States (25.3%), Iran (12.2%) and Japan (9.6%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.